SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors cheer its record revenue, positive EBITDA, and strategic acquisition of Goonhilly Earth Station. The stock is a focal point of intense community debate, with bulls citing multi-year growth potential and upcoming contract catalysts, while others monitor the volatility surrounding its high-volume price swings.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing strong trading activity driven by a triple-digit revenue surge and increased guidance for the fiscal year, with investors debating the potential for long-term growth and the impact of upcoming reimbursement changes. The community is actively discussing the company's path to profitability, the commercial outlook for its DefenCath and Rezzayo products, and speculation regarding potential strategic moves or acquisition interest from larger dialysis providers.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors rally around the company's aggressive expansion into agentic AI for broadband networks and its integration into the AI-native 6G and cloud infrastructure ecosystem. The community is heavily focused on intense call option activity and potential upcoming milestones, viewing the stock as an undervalued play transitioning into a critical component of the AI supply chain.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant market volatility as investors weigh strong growth and a series of strategic partnerships against bearish sentiment driven by high short interest and macroeconomic headwinds. The community is closely watching upcoming legal catalysts, including a high-stakes antitrust damages proceeding involving PriceRunner, which many believe is a pivotal factor for the stock's future performance.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is seeing heightened investor activity and volatility following the launch of a new energy subsidiary focused on battery storage systems for data centers and industrial infrastructure. The community is actively debating the company's strategic pivot toward AI-linked energy demands, with options traders heavily positioning for long-term price movement despite mixed sentiment regarding executive leadership and ongoing recall challenges.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

Robinhood Ventures Fund (RVI) is seeing intense volatility and massive volume as retail traders speculate on its private AI-heavy portfolio, specifically its exposure to high-growth firms like Databricks and OpenAI. The community is sharply divided, with bulls viewing the fund as a rare, accessible play on pre-IPO tech giants while skeptics warn that the current market price represents an unsustainable premium to the fund's underlying net asset value.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum as investors position themselves ahead of the upcoming AUA Annual Meeting, where the company is slated to present practice-changing extended follow-up data for its prostate cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with widespread speculation regarding a potential buyout and excitement over the firm's strengthened balance sheet and upcoming BLA submission.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors anticipate a major shift toward an AI and cloud infrastructure powerhouse through its acquisition of Northern Data, fueling intense speculation about a potential short squeeze. Community sentiment remains highly charged, with bulls focused on Tether's strategic backing and insider alignment while aggressively countering bearish narratives regarding earnings and valuation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is surging as the market re-rates the company as a critical AI infrastructure play following better-than-expected earnings and a massive boost in hyperscaler AI orders. Investors are focused on its strategic shift toward networking, silicon, and data center connectivity, with many noting its newfound momentum as it breaks toward record highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Stifel lowered the firm's price target on DraftKings to $44 from $46.</li><li>Guggenheim has also lowered the firm's price target on DraftKings to $42 from $45.</li><li>JPMorgan said that Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective.&nbsp;</li></ul>Shares of DraftKings (<a href="https://stocktwits.com/symbol/DKNG">DKNG</a>) fell more than 6% on Friday after several analysts slashed their price targets on the stock ahead of its expected fourth quarter (Q4) earnings results on Monday.&nbsp;<h2 class="st-heading-2">Price Cuts</h2>Stifel lowered the firm's price target on DraftKings to $44 from $46 and kept a ‘Buy’ rating on the shares.The firm said it has approached Q4 earnings for the online gambling group cautiously despite mostly attractive valuations, noting that it tactically favors DraftKings in the near-term given NBA handle share momentum, de-risked consensus FY26 (fiscal year 2026) estimates, potential upside from the Winter Olympics and World Cup.&nbsp;Guggenheim also lowered the firm's price target on DraftKings to $42 from $45 and kept a ‘Buy’ rating on the shares after updating the firm's model for Q4 and "an initially more conservative" 2026 outlook.&nbsp;Given recent guidance challenges, it would be prudent for DraftKings to start 2026 in "a very reasonable zone and hopefully exceed expectations throughout the year," the analyst said in a note.&nbsp;JPMorgan last week also lowered the firm's price target on DraftKings to $41 from $42 and kept an ‘Overweight’ rating on the shares.&nbsp;Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective, the analyst said.&nbsp;<h2 class="st-heading-2">Upcoming Q4 Earnings</h2>Draftkings is expected to post a revenue of $1.97 billion in Q4, according to data from fiscal.ai.&nbsp;It had missed analyst estimates for third quarter revenue.&nbsp;The company is also expected to report a &nbsp;profit of $0.12 per share in the quarter. It posted a loss of $0.28 per share in the corresponding quarter of 2024.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DKNG trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;One user said that the gaming segment “is filled with too much risk from all angles.”&nbsp;“And it’s a low margin business to be home with. Risk reward is not in the bulls camp,” they added.<stembedurl>https://stocktwits.com/Balls_deeper/message/643458827</stembedurl>One bullish user said that they are adding more of Draftkings stock amid the selloff.<stembedurl>https://stocktwits.com/howyee1234/message/643455001</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp; &nbsp;

In this photo illustration, the logo of DraftKings Inc. is displayed on a smartphone screen. 

DraftKings Shares Are Falling Today – Here’s Why

Analysts from Stifel, JPMorgan and Guggenheim have slashed their price target on Draftkings ahead of its Q4 earnings due Monday.

Equity

<ul class="summary-bullets"><li>Artemis II is slated to launch no earlier than Feb.6.&nbsp;</li><li>Intuitive will track the radio waves emitted by the Orion spacecraft during the 10-day journey to gauge its real-time position and velocity.&nbsp;</li><li>There are no funds involved in the collaboration.</li></ul>Shares of Intuitive Machines (LUNR) rose over 3% after-hours on Monday after the company said that it was selected by space agency NASA to track the Artemis II Mission.Intuitive is now part of 34 global volunteers chosen by the agency to track the mission around the Moon.The mission, the first of the Artemis program with crew onboard, is slated to launch no earlier than Feb.6.<h2 class="st-heading-2">How Will Artemis Aid The Mission?</h2>Intuitive<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.intuitivemachines.com/post/nasa-selects-intuitive-machines-to-support-tracking-for-artemis-ii"> said</a> that it will support the mission using its Space Data Network (SDN) and ground station infrastructure. The company will track the radio waves emitted by the Orion spacecraft with four astronauts aboard during the 10-day journey to gauge its real-time position and velocity.“In partnership with NASA, tracking Artemis II is another opportunity to strengthen and expand our Space Data Network…We look forward to providing resilient, persistent networking for future Artemis campaign missions and our commercial partners,” said Intuitive Machines CEO Steve Altemus.The company will also submit data to NASA for analysis, helping the agency identify ways to improve future moon and Mars mission support. There are no funds involved in the collaboration, it noted.Past And Future Artemis MissionsIntuitive previously tracked Artemis 1, a crewless mission under the program to the moon. Intuitive tracked the spacecraft then to more than 270,000 miles from Earth, breaking records.Artemis 2 is a key part of NASA’s larger Artemis program aimed at taking humans back to the surface of the moon since after the Apollo program in the 20th century.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LUNR stock stayed within the ‘bullish’ territory while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user termed the stock ‘undervalued.’<stembedurl>https://www.stocktwits.com/Thinking101/message/642944386</stembedurl>Another opined that the company is showing strong growth and demand. “The future here is very large a $100BILLION market cap company in the making,” they wrote.<stembedurl>https://www.stocktwits.com/romanaround/message/642943025</stembedurl><a href="https://stocktwits.com/symbol/LUNR">LUNR stock</a> has fallen 13% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-cvm-shares-rally-today/cmyJRm7R4hj">Why DID CVM Shares Rally Over 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Intuitive Machines, Inc. is displayed on a smartphone screen, with the company's blue branding visible in the background, on May 11, 2025, in Chongqing, China.

LUNR Shares Edge Up 3% After Hours — What's Intuitive’s Role In NASA’s Artemis Program?

Intuitive is now part of 34 global volunteers chosen by the agency to track Artemis II. 

<ul class="summary-bullets"><li>Culper believes that T1 is ineligible for 45X tax credits, and forthcoming treasury guidance will be a “death blow” to the company.&nbsp;</li><li>Culper alleged that T1 has rebranded itself as an all American solar module manufacturer while remaining operationally and economically subject to China-based Trina Solar, a foreign entity of concern.&nbsp;</li><li>Culper also noted discrepancies between T1’s reported sales to Trina and Trina’s reported purchases from T1.</li></ul>T1 Energy shares slumped on Wednesday after activist short seller Culper Research published a critical short report on the company and said it has taken a short position against the firm.&nbsp;“We are short T1 Energy, a failed EV battery SPAC that has rebranded itself an all American solar module manufacturer while remaining operationally and economically subject to China-based Trina Solar, a foreign entity of concern (FEOC),” Culper said in its report. &nbsp;“We have little faith in management, nor the Company’s disclosures and financial reporting. T1 is already subject to scrutiny by the U.S. Securities and Exchange Commission, Department of Justice, and U.S. Customs, and we believe faces massive liabilities stemming from these probes, and shares are headed far lower” it said.&nbsp;<h2 class="st-heading-2">Culper’s Allegations</h2>As per Culper’s report, T1 was sued by RWE Clean Energy after RWE terminated its offtake agreement on December 19, 2025. The lawsuit alleged that T1 misrepresented its customer base, failed to provide module audits, failed to deliver compliant modules, and breached confidentiality provisions. Culper also claimed that T1 has not yet disclosed either the termination or the lawsuit.Culper believes that T1 is ineligible for 45X tax credits (Advanced Manufacturing Production Credit) , and forthcoming treasury guidance explicitly designed to “prevent entities from evading, circumventing, or abusing” existing FEOC provisions will be a “death blow.” Experts also warn that certain Chinese groups may be entirely blacklisted, which could risk T1’s eligibility altogether.&nbsp;<h2 class="st-heading-2">Financial Irregularities</h2>Culper also raised irregularities in T1’s financial reporting. It noted discrepancies between T1’s reported sales to Trina and Trina’s reported purchases from T1. As per the report, T1 has accrued $59.7 million due to Trina, which is equivalent to 83% of its total consolidated gross profit for the nine months ended Sept. 2025.Culper Research views T1 as wholly uninvestible. “Absent 45X credits, T1’s business model fails. The Wilmer facility has minimal standalone value without Trina’s materials, operations, personnel, customers, and financial support, and as Treasury enforcement tightens, we believe T1 threatens permanent ineligibility,” it said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around TE trended in ‘extremely bullish’ territory amid ‘high’ message volume.Shares of the company have risen nearly 11% year-to-date.&nbsp; &nbsp;

T1 Energy shares slumped on Wednesday after activist short seller Culper Research published a critical short report on the company

T1 Energy Dives 12% As Culper Research Takes A Short Position Saying Company Is A ‘Failed EV Battery SPAC’

Culper Research said it has little faith in T1’s management, nor the company’s disclosures and financial reporting and said that shares are headed far lower. 

<ul class="summary-bullets"><li>CEO John C. Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships.</li><li>For the third quarter, the company reported total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners.</li><li>Novavax now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range. &nbsp;</li></ul>Novavax (NVAX) CEO John C. Jacobs on Thursday detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships with Sanofi and Takeda.“Our new strategy is centered on amplifying the impact of our technology platform through collaborations with other biopharmaceutical companies and a new diversified pipeline, and this represents a strategic and thoughtful departure away from a single focus on the resource-intense commercialization of one product, our COVID-19 vaccine,” the CEO said.Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships in the form of upfront payments and milestones earned to date.The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program. It also renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan.<h2 class="st-heading-2">Q3 Numbers</h2>For the third quarter, the company <a href="https://stocktwits.com/symbol/NVAX">reported</a> total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners. This marks a dip from the $80 million reported in the corresponding quarter of 2024, but above an analyst estimate of $44.87 million.The company now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range, up from its previous guidance of $1 billion to $1.05 billion. This is primarily owing to better than previously expected licensing, royalty, and other revenue.The company’s loss per share came in at $1.25 in the third quarter, above an expected loss of $1.13.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits"><figcaption>NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits</figcaption></figure>NVAX stock is down by about 4% this year and by about 14% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-refrains-from-backing-down-in-metsera-acquisition-battle-sweetens-bid-further/cL2twEeRER8">Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program.

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program and renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan. 

<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

<ul class="summary-bullets"><li>Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</li><li>In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.</li><li>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma. &nbsp;</li></ul>Shares of Inhibrx Biosciences (INBX) jumped over 62% in the pre-market session on Friday after the company announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.The company investigated Ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma, a rare type of bone cancer that develops in the cartilage cells, most often affecting the pelvis, thigh, or upper arm.<h2 class="st-heading-2">What Was Observed In The Study?</h2>In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://inhibrxbiosciences.investorroom.com/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts">study</a>, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared with placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months with placebo. Progression-free survival (PFS) is the time a patient lives with a disease without worsening, from the start of treatment until disease progression or death.According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.<h2 class="st-heading-2">Safety Concerns</h2>Ozekibart was generally well tolerated, with a manageable safety profile, the company said. However, one liver damage-related fatal event occurred early in the study, it noted. The company mitigated the risk during the course of the trial by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, thereby reducing the overall incidence of liver-related treatment-related adverse events, it added.Inhibrx is also studying the drug in colorectal cancer and ewing sarcoma in combination with other drugs. While colorectal cancer is a cancer that forms in the colon or rectum, ewing sarcoma is a type of cancer that forms in the bone or soft tissue.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/INBX"> INBX stock </a>jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Retail chatter around the stock jumped about 985% over the past 24 hours, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally as high as over $70, citing the company’s first-mover advantage in developing drugs for chondrosarcoma.<stembedurl>https://stocktwits.com/spaumaki/message/633545900</stembedurl>INBX stock is up 84% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reliance-increases-crude-imports-from-middle-east-u-s-amid-russian-crude-sanctions-report/cLGJZgVR3so">Reliance Increases Crude Imports From Middle East, U.S. Amid Russian Crude Sanctions: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is INBX Stock Rising Today?

Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”SANA shares traded 35% higher at the time of writing.Jackson <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ericjackson/status/1978460243001782649">took</a> to the social media platform X, opining that <a href="https://stocktwits.com/symbol/SANA">SANA stock</a> would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.<figure class="image"><img style="aspect-ratio:592/407;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_11_35_05_AM_png_c72bd5dfe0.webp" alt="Screenshot 2025-10-15 at 11.35.05 AM.png" width="592" height="407"><figcaption>Screenshot of Jackson's X Post</figcaption></figure>Transplants generally require lifelong immunosuppression, but Sana’s technology removes the need for them, Jackson noted. ‘That’s not hype — it’s human proof that Sana’s “hypoimmune” cells can hide from the immune system and work normally. If it works in diabetes, it could work for liver, heart, muscle, or brain cells next,’ he wrote, expressing hopes for the technology powering future therapies for autoimmune diseases, cancer, and even organ regeneration.Jackson further highlighted that the biotech company’s balance sheet is solid and added that he was long on SANA stock. He also highlighted several upsides, including 9 million people with diabetes worldwide who might benefit from the treatment.“If Sana’s therapy costs $100K per patient (typical for cell therapy) and reaches only 10% of them, that’s $90B in revenue potential over time,” Jackson said.On Stocktwits, retail sentiment around SANA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.SANA stock has more than tripled this year and gained about 41% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-unveils-expanded-facility-in-texas-aimed-at-doubling-production-of-hyperkalemia-drug/ch6nzBiR3No">AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’

Jackson added that he was long on the stock, while highlighting that the biotech company’s balance sheet is solid.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

iShares Trust - iShares Russell 3000 ETF

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it 

Cerebras ($CRBS) IPO day is Thursday, how are you playing it?  
 
Drop a comment with your strategy.

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest IWV News

IWVBlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF